{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:30:46Z","timestamp":1790947846700,"version":"4.1.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA240139"],"award-info":[{"award-number":["P30CA240139"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.celrep.2026.117292","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T09:10:08Z","timestamp":1776676208000},"page":"117292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Durable control of autoimmunity requires sustained stimulation of regulatory T cells"],"prefix":"10.1016","volume":"45","author":[{"given":"Janika","family":"P\u00f5der","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aixin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Albalaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Klatzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro V.","family":"Villarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Serafini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7174-0434","authenticated-orcid":false,"given":"Thomas R.","family":"Malek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.celrep.2026.117292_bib1","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","article-title":"Interleukin-2 and regulatory T cells in graft-versus-host disease","volume":"365","author":"Koreth","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.celrep.2026.117292_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103172","article-title":"The universal effects of low-dose interleukin-2 across 13 autoimmune diseases in a basket clinical trial","volume":"144","author":"Lorenzon","year":"2024","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.celrep.2026.117292_bib3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","article-title":"Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial","volume":"78","author":"Rosenzwajg","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.celrep.2026.117292_bib4","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMoa1105143","article-title":"Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis","volume":"365","author":"Saadoun","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.celrep.2026.117292_bib5","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nri3823","article-title":"The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases","volume":"15","author":"Klatzmann","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.celrep.2026.117292_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.648408","article-title":"Low-Dose IL-2 Therapy in Autoimmune and Rheumatic Diseases","volume":"12","author":"Gra\u00dfhoff","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.celrep.2026.117292_bib7","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(25)00262-4","article-title":"Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial","volume":"405","author":"Bensimon","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.celrep.2026.117292_bib8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaut.2015.01.001","article-title":"Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients","volume":"58","author":"Rosenzwajg","year":"2015","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.celrep.2026.117292_bib9","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2213-8587(13)70113-X","article-title":"Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1\/2 randomised, double-blind, placebo-controlled trial","volume":"1","author":"Hartemann","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.celrep.2026.117292_bib10","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1182\/bloodadvances.2023009729","article-title":"Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease","volume":"7","author":"Wobma","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.celrep.2026.117292_bib11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2337\/db24-0439","article-title":"Emerging Concepts and Success Stories in Type 1 Diabetes Research: A Road Map for a Bright Future","volume":"74","author":"Mallone","year":"2025","journal-title":"Diabetes"},{"key":"10.1016\/j.celrep.2026.117292_bib12","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1136\/ard-2022-222501","article-title":"Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial","volume":"81","author":"Humrich","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.celrep.2026.117292_bib13","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.4049\/jimmunol.130.5.2203","article-title":"The fate of interleukin-2 after in vivo administration","volume":"130","author":"Donohue","year":"1983","journal-title":"J. Immunol."},{"key":"10.1016\/j.celrep.2026.117292_bib14","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.4049\/jimmunol.135.4.2865","article-title":"In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2","volume":"135","author":"Lotze","year":"1985","journal-title":"J. Immunol."},{"key":"10.1016\/j.celrep.2026.117292_bib15","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41590-022-01179-1","article-title":"Dynamic transcriptional activity and chromatin remodeling of regulatory T cells after varied duration of interleukin-2 receptor signaling","volume":"23","author":"Moro","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.celrep.2026.117292_bib16","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cncr.10631","article-title":"Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma","volume":"95","author":"Eton","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.celrep.2026.117292_bib17","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41577-022-00680-w","article-title":"Engineering IL-2 for immunotherapy of autoimmunity and cancer","volume":"22","author":"Hernandez","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.celrep.2026.117292_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104539","article-title":"A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases","volume":"90","author":"Raeber","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.celrep.2026.117292_bib19","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.4049\/jimmunol.1800907","article-title":"IL-2\/CD25: A Long-Acting Fusion Protein That Promotes Immune Tolerance by Selectively Targeting the IL-2 Receptor on Regulatory T Cells","volume":"201","author":"Ward","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.celrep.2026.117292_bib20","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.2337\/db20-0186","article-title":"Persistent IL-2 Receptor Signaling by IL-2\/CD25 Fusion Protein Controls Diabetes in NOD Mice by Multiple Mechanisms","volume":"69","author":"Ward","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.celrep.2026.117292_bib21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4049\/jimmunol.2100078","article-title":"Mouse IL-2\/CD25 Fusion Protein Induces Regulatory T Cell Expansion and Immune Suppression in Preclinical Models of Systemic Lupus Erythematosus","volume":"207","author":"Xie","year":"2021","journal-title":"J. Immunol."},{"key":"10.1016\/j.celrep.2026.117292_bib22","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.4049\/jimmunol.1103768","article-title":"IL-2 receptor signaling is essential for the development of Klrg1+ terminally differentiated T regulatory cells","volume":"189","author":"Cheng","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.celrep.2026.117292_bib23","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20192362","article-title":"Single-cell RNA sequencing of murine islets shows high cellular complexity at all stages of autoimmune diabetes","volume":"217","author":"Zakharov","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.celrep.2026.117292_bib24","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1073\/pnas.1423769112","article-title":"Population dynamics of islet-infiltrating cells in autoimmune diabetes","volume":"112","author":"Magnuson","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2026.117292_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059701","article-title":"Defining the transcriptional and cellular landscape of type 1 diabetes in the NOD mouse","volume":"8","author":"Carrero","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.celrep.2026.117292_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.111248","article-title":"Interleukin-2 receptor signaling acts as a checkpoint that influences the distribution of regulatory T cell subsets","volume":"27","author":"Shouse","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.celrep.2026.117292_bib27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1084\/jem.20131142","article-title":"CCR7 provides localized access to IL-2 and defines homeostatically distinct regulatory T cell subsets","volume":"211","author":"Smigiel","year":"2014","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.celrep.2026.117292_bib28","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1182\/blood-2014-07-587493","article-title":"Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy","volume":"124","author":"Van Gool","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.celrep.2026.117292_bib29","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.4049\/jimmunol.1502570","article-title":"Human CD56bright NK Cells: An Update","volume":"196","author":"Michel","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.celrep.2026.117292_bib30","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/s41392-024-02005-w","article-title":"Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.celrep.2026.117292_bib31","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41584-021-00707-x","article-title":"Interleukin-2 and regulatory T cells in rheumatic diseases","volume":"17","author":"Kolios","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.celrep.2026.117292_bib32","doi-asserted-by":"crossref","first-page":"lqaf150","DOI":"10.1093\/nargab\/lqaf150","article-title":"Benchmarking unsupervised methods for inferring TCR specificity","volume":"7","author":"Jouannet","year":"2025","journal-title":"NAR Genom. Bioinform."},{"key":"10.1016\/j.celrep.2026.117292_bib33","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/s41592-022-01578-0","article-title":"VDJdb in the pandemic era: a compendium of T cell receptors specific for SARS-CoV-2","volume":"19","author":"Goncharov","year":"2022","journal-title":"Nat. Methods"},{"key":"10.1016\/j.celrep.2026.117292_bib34","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1093\/bioinformatics\/btx286","article-title":"McPAS-TCR: a manually curated catalogue of pathology-associated T cell receptor sequences","volume":"33","author":"Tickotsky","year":"2017","journal-title":"Bioinformatics"},{"key":"10.1016\/j.celrep.2026.117292_bib35","doi-asserted-by":"crossref","first-page":"D339","DOI":"10.1093\/nar\/gky1006","article-title":"The Immune Epitope Database (IEDB): 2018 update","volume":"47","author":"Vita","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.celrep.2026.117292_bib36","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.immuni.2008.03.016","article-title":"Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction","volume":"28","author":"Tang","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.celrep.2026.117292_bib37","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1084\/jem.20100209","article-title":"IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells","volume":"207","author":"Grinberg-Bleyer","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.celrep.2026.117292_bib38","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.clim.2014.02.003","article-title":"Sustained stimulation and expansion of Tregs by IL2 control autoimmunity without impairing immune responses to infection, vaccination and cancer","volume":"151","author":"Churlaud","year":"2014","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.celrep.2026.117292_bib39","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.2337\/db13-0669","article-title":"\u03b2-cell-specific IL-2 therapy increases islet Foxp3+Treg and suppresses type 1 diabetes in NOD mice","volume":"62","author":"Johnson","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.celrep.2026.117292_bib40","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1182\/blood-2016-02-702852","article-title":"Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease","volume":"128","author":"Koreth","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.celrep.2026.117292_bib41","doi-asserted-by":"crossref","first-page":"179ra43","DOI":"10.1126\/scitranslmed.3005265","article-title":"Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease","volume":"5","author":"Matsuoka","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.celrep.2026.117292_bib42","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1182\/bloodadvances.2019000631","article-title":"Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children","volume":"3","author":"Whangbo","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.celrep.2026.117292_bib43","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aat5861","article-title":"Molecular diversification of regulatory T cells in nonlymphoid tissues","volume":"3","author":"DiSpirito","year":"2018","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.celrep.2026.117292_bib44","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/s41577-021-00519-w","article-title":"Tissue regulatory T cells: regulatory chameleons","volume":"21","author":"Mu\u00f1oz-Rojas","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.celrep.2026.117292_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104998","article-title":"Profiling of Tregs across tissues reveals plasticity in ST2 expression and hierarchies in tissue-specific phenotypes","volume":"25","author":"Spath","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.celrep.2026.117292_bib46","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-45738-4","article-title":"The amphiregulin\/EGFR axis has limited contribution in controlling autoimmune diabetes","volume":"13","author":"Raugh","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.celrep.2026.117292_bib47","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2337\/db22-0482","article-title":"Immunotherapy With Low-Dose IL-2\/CD25 Prevents \u03b2-Cell Dysfunction and Dysglycemia in Prediabetic NOD Mice","volume":"72","author":"Qureshi","year":"2023","journal-title":"Diabetes"},{"key":"10.1016\/j.celrep.2026.117292_bib48","doi-asserted-by":"crossref","first-page":"7776","DOI":"10.1038\/s41598-025-91636-2","article-title":"Treg derived Amphiregulin protects from murine lupus nephritis via tissue reparative effects","volume":"15","author":"Ehnold","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.celrep.2026.117292_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102829","article-title":"The Amphiregulin\/EGFR axis protects from lupus nephritis via downregulation of pathogenic CD4","volume":"129","author":"Melderis","year":"2022","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.celrep.2026.117292_bib50","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jaci.2024.10.033","article-title":"Low-dose IL-2 in birch pollen allergy: A phase-2 randomized double-blind placebo-controlled trial","volume":"155","author":"Rosenzwajg","year":"2025","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.celrep.2026.117292_bib51","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202012305","article-title":"IL-10 producing type 2 innate lymphoid cells prolong islet allograft survival","volume":"12","author":"Huang","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.celrep.2026.117292_bib52","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1038\/s41467-017-02023-z","article-title":"Alternative activation generates IL-10 producing type 2 innate lymphoid cells","volume":"8","author":"Seehus","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2026.117292_bib53","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s41232-023-00272-8","article-title":"Group 2 innate lymphoid cells and their surrounding environment","volume":"43","author":"Naito","year":"2023","journal-title":"Inflamm. Regen."},{"key":"10.1016\/j.celrep.2026.117292_bib54","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.immuni.2017.10.015","article-title":"Interleukin-33-Activated Islet-Resident Innate Lymphoid Cells Promote Insulin Secretion through Myeloid Cell Retinoic Acid Production","volume":"47","author":"Dalmas","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.celrep.2026.117292_bib55","doi-asserted-by":"crossref","first-page":"5408","DOI":"10.1038\/s41467-022-33171-6","article-title":"Liver group 2 innate lymphoid cells regulate blood glucose levels through IL-13 signaling and suppression of gluconeogenesis","volume":"13","author":"Fujimoto","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2026.117292_bib56","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.1073\/pnas.0601335103","article-title":"Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis","volume":"103","author":"Bielekova","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2026.117292_bib57","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/cei.13422","article-title":"Low-dose IL-2 induces CD56","volume":"200","author":"McQuaid","year":"2020","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.celrep.2026.117292_bib58","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.3389\/fimmu.2018.01869","article-title":"Natural Killer Cells: Development, Maturation, and Clinical Utilization","volume":"9","author":"Abel","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.celrep.2026.117292_bib59","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1038\/s41467-025-60082-z","article-title":"Expression of an interleukin-2 partial agonist enhances regulatory T cell persistence and efficacy in mouse autoimmune models","volume":"16","author":"Robert","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2026.117292_bib60","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1074-7613(00)80392-1","article-title":"The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD","volume":"7","author":"Delovitch","year":"1997","journal-title":"Immunity"},{"key":"10.1016\/j.celrep.2026.117292_bib61","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: Open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.celrep.2026.117292_bib62","article-title":"Automatic Segmentation of Cervical Cells Based on Star-Convex Polygons in Pap Smear Images","volume":"10","author":"Zhao","year":"2022","journal-title":"Bioengineering (Basel)"},{"key":"10.1016\/j.celrep.2026.117292_bib63","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nbt.4096","article-title":"Integrating single-cell transcriptomic data across different conditions, technologies, and species","volume":"36","author":"Butler","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.celrep.2026.117292_bib64","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","article-title":"Comprehensive Integration of Single-Cell Data","volume":"177","author":"Stuart","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2026.117292_bib65","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/bioinformatics\/btw777","article-title":"Scater: pre-processing, quality control, normalization and visualization of single-cell RNA-seq data in R","volume":"33","author":"McCarthy","year":"2017","journal-title":"Bioinformatics"},{"key":"10.1016\/j.celrep.2026.117292_bib66","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1186\/s13059-021-02552-3","article-title":"Benchmarking UMI-based single-cell RNA-seq preprocessing workflows","volume":"22","author":"You","year":"2021","journal-title":"Genome Biol."},{"key":"10.1016\/j.celrep.2026.117292_bib67","doi-asserted-by":"crossref","first-page":"47","DOI":"10.12688\/f1000research.22139.1","article-title":"scRepertoire: An R-based toolkit for single-cell immune receptor analysis","volume":"9","author":"Borcherding","year":"2020","journal-title":"F1000Res."},{"key":"10.1016\/j.celrep.2026.117292_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.602539","article-title":"Single-Cell Transcriptomic Analyses Define Distinct Peripheral B Cell Subsets and Discrete Development Pathways","volume":"12","author":"Stewart","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.celrep.2026.117292_bib69","doi-asserted-by":"crossref","DOI":"10.1093\/gigascience\/giy083","article-title":"Clustering trees: a visualization for evaluating clusterings at multiple resolutions","volume":"7","author":"Zappia","year":"2018","journal-title":"GigaScience"},{"key":"10.1016\/j.celrep.2026.117292_bib70","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1093\/bioinformatics\/btu393","article-title":"circlize Implements and enhances circular visualization in R","volume":"30","author":"Gu","year":"2014","journal-title":"Bioinformatics"}],"container-title":["Cell Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124726003700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124726003700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:48:32Z","timestamp":1785473312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211124726003700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2211124726003700"],"URL":"https:\/\/doi.org\/10.1016\/j.celrep.2026.117292","relation":{},"ISSN":["2211-1247"],"issn-type":[{"value":"2211-1247","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Durable control of autoimmunity requires sustained stimulation of regulatory T cells","name":"articletitle","label":"Article Title"},{"value":"Cell Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.celrep.2026.117292","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117292"}}